Loading ...

Dawn Smilek, MD PhD

Immune Tolerance Network

Chief Medical Officer, Clinical Trials Group; Senior Director, Clinical and Translational Medicine, Clinical Trials Group

http://www.immunetolerance.org

Assessment Group

Autoimmune Disease

dsmilek@immunetolerance.org

Work:

415-353-4308

Mobile:

415-361-8735

Address:

Immune Tolerance Network

Committees:

NEC

,

Studies:

ITN035AI

-

A Cooperative Clinical Study of Abatacept in Multiple Sclerosis

ITN047AI

-

A Study to Determine the Immunogenicity and Oral Tolerance to Keyhole Limpet Hemocyanin

ITN059AI

-

Efficacy of Ustekinumab Followed by Abatacept for the Treatment of Psoriasis Vulgaris

ITN055AI

-

Rituximab and Belimumab for Lupus Nephritis

ITN051AI

-

Defining Immune Tolerance in ANCA-associated Vasculitis

ITN075AI

-

Brentuximab Vedotin for Systemic Sclerosis

ITN077AI

-

Best Available Therapy Vs. Autologous Hematopoietic Stem Cell Transplant For MS

ITN076AD

-

Food Exposure Allergy Suppression Trial Pilot Study

Bio:

Admin Links

Shortcuts

ITN Documents

Links